Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D05HBZ
|
|||
| Former ID |
DCL000787
|
|||
| Drug Name |
E 7974
|
|||
| Synonyms |
26510-52-1; ethyl 3-oxo-3-(pyridin-2-yl)propanoate; Ethyl picolinoylacetate; ethyl 3-oxo-3-(2-pyridyl)propionate; ethyl 3-oxo-3-pyridin-2-ylpropanoate; ethyl 3-oxo-3-(2-pyridinyl)propanoate; 3-Oxo-3-(2-pyridyl)propionic acid ethyl ester; Ethyl picolinoylacetate, 95%; ethyl 3-oxo-3-(2-pyridyl)propanoate; PubChem11088; ethyl-2-pyridoyl acetate; AC1MC5MX; AC1Q34ND; SCHEMBL601821; CHEMBL2035673; CTK4F8033; DTXSID30371376; MolPort-001-769-152; FQHXWZMJALFSJJ-UHFFFAOYSA-N; ZINC153764; Ethyl picolinoylacetate, AldrichCPR; STL131872
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Ovarian cancer [ICD-11: 2C73; ICD-10: C56; ICD-9: 183] | Phase 1 | [1] | |
| Company |
Eisai Co. Ltd.
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C24H43N3O4
|
|||
| Canonical SMILES |
CC(C)C(C=C(C)C(=O)O)N(C)C(=O)C(C(C)(C)C)NC(=O)C1CCCCN1C(C)C
|
|||
| InChI |
1S/C24H43N3O4/c1-15(2)19(14-17(5)23(30)31)26(9)22(29)20(24(6,7)8)25-21(28)18-12-10-11-13-27(18)16(3)4/h14-16,18-20H,10-13H2,1-9H3,(H,25,28)(H,30,31)/b17-14+/t18-,19-,20-/m1/s1
|
|||
| InChIKey |
FWYMMXUDTATKLG-PGLMLKKXSA-N
|
|||
| CAS Number |
CAS 610787-07-0
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
3159558, 6901604, 8796930, 12033308, 15265945, 30094103, 53414412, 53796796, 88812136, 93579995, 109458354, 111367160, 117438477, 117655976, 118046519, 118838942, 123082614, 124990818, 125387063, 126604419, 126647988, 127884251, 131378153, 131497547, 134339271, 135563810, 136911175, 137049919, 139661615, 143460412, 143503148, 143801039, 152245305, 160673496, 160821459, 160973512, 162207227, 162826350, 163371254, 163786157, 164822405, 169491328, 174535761, 184569788, 185977859, 223459621, 223523383, 224003931, 226904383, 249780390
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Tubulin (TUB) | Target Info | Inhibitor | [1] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Emerging drugs for ovarian cancer. Expert Opin Emerg Drugs. 2008 Sep;13(3):523-36. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.